GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The ...